Research Study

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Principal Investigator 
Mark FitzGerald

Overview

Body Locations and Systems 
Asthma
ClinicalTrials.gov# 
NCT02134028
Status 
Recruiting
Study Start/End 
Oct 6, 2016 to Sep 30, 2019
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Linda Hui, Research Coordinator
Phone 
604-875-5698
Purpose of Study 

Primary Objective:

Evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma study.

Secondary Objectives:

Evaluate the efficacy of dupilumab in patients with asthma who participated in a previous dupilumab asthma clinical study.

Evaluate dupilumab in patients with asthma who participated in a previous dupilumab asthma clinical study, with regards to:

  • Systemic exposure
  • Anti-drug antibodies
  • Biomarkers
Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.